2,6-substituted-4-monosubstituted amino-pyrimidine as prostaglandin D2 receptor antagonists

Disclosed are the compounds 1-{ 6-[2-(2,4-Dicbloro-phenyl)-ethylamino]-2-methyl-pyrimidin-4-yl} -pyrrolidine-3-carboxylic acid, 2-(1-{ 2-Methoxy-6-[2-(4-trifluorometboxy-phenyl)-ethylamino]-pyrimidin-4-yl} -piperidin-3-yl)-2methyl- propionic acid, 2-[3-{ 6-[2-(2,4-Dichloro-phenyl)-ethylamino]-2-meth...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	GARDNER, CHARLES J, GILLESPY, TIMOTHY ALAN, AGUIAR, JOACY C, HARRIS, KEITH JOHN, STEFANY, DAVID
Format:	Patent
Sprache:	eng
Schlagworte:	CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page
container_issue
container_start_page
container_title
container_volume
creator	GARDNER, CHARLES J GILLESPY, TIMOTHY ALAN AGUIAR, JOACY C HARRIS, KEITH JOHN STEFANY, DAVID
description	Disclosed are the compounds 1-{ 6-[2-(2,4-Dicbloro-phenyl)-ethylamino]-2-methyl-pyrimidin-4-yl} -pyrrolidine-3-carboxylic acid, 2-(1-{ 2-Methoxy-6-[2-(4-trifluorometboxy-phenyl)-ethylamino]-pyrimidin-4-yl} -piperidin-3-yl)-2methyl- propionic acid, 2-[3-{ 6-[2-(2,4-Dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -5-(l-hydroxy-1-methylethyl)-phenyl]-propan-2-ol, [6-(3-Amino-piperidin-l-yl)-2-methoxy-pyrimidin-4-yl]-[2-(2,4-dichloro-phenyI)-ethyl]-amine, [6-(4-amino-piperidin-l-yl)-2-methoxy-pyrimidin-4-yI]-[2-(2,4-dichloro-phenyl)-ethyl]-amine, N-(1-{ 6-[2-(2,4-Dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -piperidin-4-yl)-acetamide, S-{ 6-[2-(2,4-0ichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -1-methyl-2,3-dihydro-1H-indole-2-carboxylic acid, 2-Methyl-propane-2-sulfonic acid [2-(3-{ 6-[2-(2,4-dichloro-phenyl)-ethylamino]-2-methoxypyrimidin-4-yl} -phenyI)-2-methyl-propionyl]-amide, 10 N,N-dimethylamide-2-sulfonic acid [2-(3- { 6-[2-(2,4-dich1oro-phenyl)-ethylamino]-2-methoxypyrimidin-4-yl} -phenyl)-2-methyl-propionyl]-amide, 2-(3-{ 6-[2-(2,4-dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -phenyl)-2-methyl-1-thiomorpholin-4-yl-propan-1-one, 2-(3-{ 6-[2-(2,4-Dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -phenyl)isobutyramide, 2-(3-{ 6-[2-(2,4-dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -phenyl)-N,N dimethylisobutyramide, (1-{ 6-[2-(2,4-Dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -piperidin-3-yl)-acetic acid, 1-{ 2-Methoxy-6-[2-(4-tritluoromethoxy-phenyl)-ethylamino]-pyrimidin-4-yl} -piperidine-3-carboxylic acid, N-(1-{ 2-Methoxy-6-[2-(4-trifluoromethoxy-phenyl)-ethylamino]-pyrimidin-4-yl} -piperidine-3-carbonyl)-methanesulfonamide,s-{ 6-[2-(2,4-dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -1-methyl-2,3-dihydro-IH-indole-2-carboxylic acid ethyl ester, (1-{ 6-[2-(2,4-dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -piperidin-3-yl)-acetic acid ethyl ester, N-(1-{ 6-[2-(2,4-Dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -piperidine-3-carbonyl)methanesulfonamide Ethanesulfonic acid (1-{ 6-[2-(2,4-dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} piperidine-3-carbonyl)-amide, 2-Methyl-propane-2-sulfonic acid (1-{ 6-[2-(2,4-dichlorophenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -piperidine-3-earbonyl)-amide, N-(1-{ 6-[2-(2,4-Dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -piperidine-3-carbonyl), trifluoro-methanesulfonamide, 1-{ 6-[2-(2,4-Dichloro-phenyl)-ethylamino]-2
format	Patent
fullrecord	<record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_NZ571793A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>NZ571793A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_NZ571793A3</originalsourceid><addsrcrecordid>eNrjZIg20jHTLS5NKi7JLCktSU3RNdHNzc_LRxJRSMzNzMvXLagsyszNTMnMS1VILFYoKMovLklMz0nMA4oouBgpFKUmpxaU5BcpJOYBxfPzMotLinkYWNMSc4pTeaE0N4Ocm2uIs4duakF-fGpxQWJyal5qSbxflKm5obmlsaMxQQUAN4Q63A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>2,6-substituted-4-monosubstituted amino-pyrimidine as prostaglandin D2 receptor antagonists</title><source>esp@cenet</source><creator>GARDNER, CHARLES J ; GILLESPY, TIMOTHY ALAN ; AGUIAR, JOACY C ; HARRIS, KEITH JOHN ; STEFANY, DAVID</creator><creatorcontrib>GARDNER, CHARLES J ; GILLESPY, TIMOTHY ALAN ; AGUIAR, JOACY C ; HARRIS, KEITH JOHN ; STEFANY, DAVID</creatorcontrib><description>Disclosed are the compounds 1-{ 6-[2-(2,4-Dicbloro-phenyl)-ethylamino]-2-methyl-pyrimidin-4-yl} -pyrrolidine-3-carboxylic acid, 2-(1-{ 2-Methoxy-6-[2-(4-trifluorometboxy-phenyl)-ethylamino]-pyrimidin-4-yl} -piperidin-3-yl)-2methyl- propionic acid, 2-[3-{ 6-[2-(2,4-Dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -5-(l-hydroxy-1-methylethyl)-phenyl]-propan-2-ol, [6-(3-Amino-piperidin-l-yl)-2-methoxy-pyrimidin-4-yl]-[2-(2,4-dichloro-phenyI)-ethyl]-amine, [6-(4-amino-piperidin-l-yl)-2-methoxy-pyrimidin-4-yI]-[2-(2,4-dichloro-phenyl)-ethyl]-amine, N-(1-{ 6-[2-(2,4-Dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -piperidin-4-yl)-acetamide, S-{ 6-[2-(2,4-0ichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -1-methyl-2,3-dihydro-1H-indole-2-carboxylic acid, 2-Methyl-propane-2-sulfonic acid [2-(3-{ 6-[2-(2,4-dichloro-phenyl)-ethylamino]-2-methoxypyrimidin-4-yl} -phenyI)-2-methyl-propionyl]-amide, 10 N,N-dimethylamide-2-sulfonic acid [2-(3- { 6-[2-(2,4-dich1oro-phenyl)-ethylamino]-2-methoxypyrimidin-4-yl} -phenyl)-2-methyl-propionyl]-amide, 2-(3-{ 6-[2-(2,4-dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -phenyl)-2-methyl-1-thiomorpholin-4-yl-propan-1-one, 2-(3-{ 6-[2-(2,4-Dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -phenyl)isobutyramide, 2-(3-{ 6-[2-(2,4-dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -phenyl)-N,N dimethylisobutyramide, (1-{ 6-[2-(2,4-Dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -piperidin-3-yl)-acetic acid, 1-{ 2-Methoxy-6-[2-(4-tritluoromethoxy-phenyl)-ethylamino]-pyrimidin-4-yl} -piperidine-3-carboxylic acid, N-(1-{ 2-Methoxy-6-[2-(4-trifluoromethoxy-phenyl)-ethylamino]-pyrimidin-4-yl} -piperidine-3-carbonyl)-methanesulfonamide,s-{ 6-[2-(2,4-dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -1-methyl-2,3-dihydro-IH-indole-2-carboxylic acid ethyl ester, (1-{ 6-[2-(2,4-dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -piperidin-3-yl)-acetic acid ethyl ester, N-(1-{ 6-[2-(2,4-Dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -piperidine-3-carbonyl)methanesulfonamide Ethanesulfonic acid (1-{ 6-[2-(2,4-dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} piperidine-3-carbonyl)-amide, 2-Methyl-propane-2-sulfonic acid (1-{ 6-[2-(2,4-dichlorophenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -piperidine-3-earbonyl)-amide, N-(1-{ 6-[2-(2,4-Dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -piperidine-3-carbonyl), trifluoro-methanesulfonamide, 1-{ 6-[2-(2,4-Dichloro-phenyl)-ethylamino]-2-methoxy-pyrlmidin-4-yl} -piperidine-3-carboxylic acid(IH-tetrazol-5-yl)-amide, 1-{ 6-[2-(2,4-Dichloro-phenyl)-ethylamino]-2-methoxy-pyrlmidin-4-yl} -piperidine-3-carboxylic acid amide, 1-{ 6-[2-(2,4-Dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -piperidine-3-carboxylic acid dimethylamide, N,N-Dimethylamide-2-sulfonic acid 1-{ 6-[2-(2,4-dichloro-phenyl)-ethylamino]-2-methoxypyrimidin-4-yl} -piperidine-3-carboxamide, 5-{ 2-Methoxy-6-[2-(4-tritluoromethoxy-phenyl)-ethylamino]-pyrimidin-4-yl} thiophene-2-carboxylic acid, or 5-{ 6-[2-(2,4-Dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -2,3-dihydrobenzofuran-2-carboxylic acid, or a pharmaceutically acceptable salt, hydrate, or solvate thereof. Also Use of the compound or a pharmaceutically acceptable salt, hydrate or solvate thereof according in the manufacture of a medicament for treating an allergic disease, systemic mastocytosis. a disorder accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, a disease accompanied by itch, a disease which is generated secondarily as a result of behaviour accompanied by itch, inflammation.,chronic obsttuctive pulmonary diseases, ischemic reperfusion injury cerebrovascular accident, chronic rheumatoid arthritism, pleurisy or ulcerative colitis.</description><language>eng</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2011</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20110826&DB=EPODOC&CC=NZ&NR=571793A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20110826&DB=EPODOC&CC=NZ&NR=571793A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>GARDNER, CHARLES J</creatorcontrib><creatorcontrib>GILLESPY, TIMOTHY ALAN</creatorcontrib><creatorcontrib>AGUIAR, JOACY C</creatorcontrib><creatorcontrib>HARRIS, KEITH JOHN</creatorcontrib><creatorcontrib>STEFANY, DAVID</creatorcontrib><title>2,6-substituted-4-monosubstituted amino-pyrimidine as prostaglandin D2 receptor antagonists</title><description>Disclosed are the compounds 1-{ 6-[2-(2,4-Dicbloro-phenyl)-ethylamino]-2-methyl-pyrimidin-4-yl} -pyrrolidine-3-carboxylic acid, 2-(1-{ 2-Methoxy-6-[2-(4-trifluorometboxy-phenyl)-ethylamino]-pyrimidin-4-yl} -piperidin-3-yl)-2methyl- propionic acid, 2-[3-{ 6-[2-(2,4-Dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -5-(l-hydroxy-1-methylethyl)-phenyl]-propan-2-ol, [6-(3-Amino-piperidin-l-yl)-2-methoxy-pyrimidin-4-yl]-[2-(2,4-dichloro-phenyI)-ethyl]-amine, [6-(4-amino-piperidin-l-yl)-2-methoxy-pyrimidin-4-yI]-[2-(2,4-dichloro-phenyl)-ethyl]-amine, N-(1-{ 6-[2-(2,4-Dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -piperidin-4-yl)-acetamide, S-{ 6-[2-(2,4-0ichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -1-methyl-2,3-dihydro-1H-indole-2-carboxylic acid, 2-Methyl-propane-2-sulfonic acid [2-(3-{ 6-[2-(2,4-dichloro-phenyl)-ethylamino]-2-methoxypyrimidin-4-yl} -phenyI)-2-methyl-propionyl]-amide, 10 N,N-dimethylamide-2-sulfonic acid [2-(3- { 6-[2-(2,4-dich1oro-phenyl)-ethylamino]-2-methoxypyrimidin-4-yl} -phenyl)-2-methyl-propionyl]-amide, 2-(3-{ 6-[2-(2,4-dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -phenyl)-2-methyl-1-thiomorpholin-4-yl-propan-1-one, 2-(3-{ 6-[2-(2,4-Dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -phenyl)isobutyramide, 2-(3-{ 6-[2-(2,4-dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -phenyl)-N,N dimethylisobutyramide, (1-{ 6-[2-(2,4-Dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -piperidin-3-yl)-acetic acid, 1-{ 2-Methoxy-6-[2-(4-tritluoromethoxy-phenyl)-ethylamino]-pyrimidin-4-yl} -piperidine-3-carboxylic acid, N-(1-{ 2-Methoxy-6-[2-(4-trifluoromethoxy-phenyl)-ethylamino]-pyrimidin-4-yl} -piperidine-3-carbonyl)-methanesulfonamide,s-{ 6-[2-(2,4-dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -1-methyl-2,3-dihydro-IH-indole-2-carboxylic acid ethyl ester, (1-{ 6-[2-(2,4-dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -piperidin-3-yl)-acetic acid ethyl ester, N-(1-{ 6-[2-(2,4-Dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -piperidine-3-carbonyl)methanesulfonamide Ethanesulfonic acid (1-{ 6-[2-(2,4-dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} piperidine-3-carbonyl)-amide, 2-Methyl-propane-2-sulfonic acid (1-{ 6-[2-(2,4-dichlorophenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -piperidine-3-earbonyl)-amide, N-(1-{ 6-[2-(2,4-Dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -piperidine-3-carbonyl), trifluoro-methanesulfonamide, 1-{ 6-[2-(2,4-Dichloro-phenyl)-ethylamino]-2-methoxy-pyrlmidin-4-yl} -piperidine-3-carboxylic acid(IH-tetrazol-5-yl)-amide, 1-{ 6-[2-(2,4-Dichloro-phenyl)-ethylamino]-2-methoxy-pyrlmidin-4-yl} -piperidine-3-carboxylic acid amide, 1-{ 6-[2-(2,4-Dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -piperidine-3-carboxylic acid dimethylamide, N,N-Dimethylamide-2-sulfonic acid 1-{ 6-[2-(2,4-dichloro-phenyl)-ethylamino]-2-methoxypyrimidin-4-yl} -piperidine-3-carboxamide, 5-{ 2-Methoxy-6-[2-(4-tritluoromethoxy-phenyl)-ethylamino]-pyrimidin-4-yl} thiophene-2-carboxylic acid, or 5-{ 6-[2-(2,4-Dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -2,3-dihydrobenzofuran-2-carboxylic acid, or a pharmaceutically acceptable salt, hydrate, or solvate thereof. Also Use of the compound or a pharmaceutically acceptable salt, hydrate or solvate thereof according in the manufacture of a medicament for treating an allergic disease, systemic mastocytosis. a disorder accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, a disease accompanied by itch, a disease which is generated secondarily as a result of behaviour accompanied by itch, inflammation.,chronic obsttuctive pulmonary diseases, ischemic reperfusion injury cerebrovascular accident, chronic rheumatoid arthritism, pleurisy or ulcerative colitis.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2011</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZIg20jHTLS5NKi7JLCktSU3RNdHNzc_LRxJRSMzNzMvXLagsyszNTMnMS1VILFYoKMovLklMz0nMA4oouBgpFKUmpxaU5BcpJOYBxfPzMotLinkYWNMSc4pTeaE0N4Ocm2uIs4duakF-fGpxQWJyal5qSbxflKm5obmlsaMxQQUAN4Q63A</recordid><startdate>20110826</startdate><enddate>20110826</enddate><creator>GARDNER, CHARLES J</creator><creator>GILLESPY, TIMOTHY ALAN</creator><creator>AGUIAR, JOACY C</creator><creator>HARRIS, KEITH JOHN</creator><creator>STEFANY, DAVID</creator><scope>EVB</scope></search><sort><creationdate>20110826</creationdate><title>2,6-substituted-4-monosubstituted amino-pyrimidine as prostaglandin D2 receptor antagonists</title><author>GARDNER, CHARLES J ; GILLESPY, TIMOTHY ALAN ; AGUIAR, JOACY C ; HARRIS, KEITH JOHN ; STEFANY, DAVID</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_NZ571793A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2011</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>GARDNER, CHARLES J</creatorcontrib><creatorcontrib>GILLESPY, TIMOTHY ALAN</creatorcontrib><creatorcontrib>AGUIAR, JOACY C</creatorcontrib><creatorcontrib>HARRIS, KEITH JOHN</creatorcontrib><creatorcontrib>STEFANY, DAVID</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>GARDNER, CHARLES J</au><au>GILLESPY, TIMOTHY ALAN</au><au>AGUIAR, JOACY C</au><au>HARRIS, KEITH JOHN</au><au>STEFANY, DAVID</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>2,6-substituted-4-monosubstituted amino-pyrimidine as prostaglandin D2 receptor antagonists</title><date>2011-08-26</date><risdate>2011</risdate><abstract>Disclosed are the compounds 1-{ 6-[2-(2,4-Dicbloro-phenyl)-ethylamino]-2-methyl-pyrimidin-4-yl} -pyrrolidine-3-carboxylic acid, 2-(1-{ 2-Methoxy-6-[2-(4-trifluorometboxy-phenyl)-ethylamino]-pyrimidin-4-yl} -piperidin-3-yl)-2methyl- propionic acid, 2-[3-{ 6-[2-(2,4-Dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -5-(l-hydroxy-1-methylethyl)-phenyl]-propan-2-ol, [6-(3-Amino-piperidin-l-yl)-2-methoxy-pyrimidin-4-yl]-[2-(2,4-dichloro-phenyI)-ethyl]-amine, [6-(4-amino-piperidin-l-yl)-2-methoxy-pyrimidin-4-yI]-[2-(2,4-dichloro-phenyl)-ethyl]-amine, N-(1-{ 6-[2-(2,4-Dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -piperidin-4-yl)-acetamide, S-{ 6-[2-(2,4-0ichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -1-methyl-2,3-dihydro-1H-indole-2-carboxylic acid, 2-Methyl-propane-2-sulfonic acid [2-(3-{ 6-[2-(2,4-dichloro-phenyl)-ethylamino]-2-methoxypyrimidin-4-yl} -phenyI)-2-methyl-propionyl]-amide, 10 N,N-dimethylamide-2-sulfonic acid [2-(3- { 6-[2-(2,4-dich1oro-phenyl)-ethylamino]-2-methoxypyrimidin-4-yl} -phenyl)-2-methyl-propionyl]-amide, 2-(3-{ 6-[2-(2,4-dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -phenyl)-2-methyl-1-thiomorpholin-4-yl-propan-1-one, 2-(3-{ 6-[2-(2,4-Dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -phenyl)isobutyramide, 2-(3-{ 6-[2-(2,4-dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -phenyl)-N,N dimethylisobutyramide, (1-{ 6-[2-(2,4-Dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -piperidin-3-yl)-acetic acid, 1-{ 2-Methoxy-6-[2-(4-tritluoromethoxy-phenyl)-ethylamino]-pyrimidin-4-yl} -piperidine-3-carboxylic acid, N-(1-{ 2-Methoxy-6-[2-(4-trifluoromethoxy-phenyl)-ethylamino]-pyrimidin-4-yl} -piperidine-3-carbonyl)-methanesulfonamide,s-{ 6-[2-(2,4-dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -1-methyl-2,3-dihydro-IH-indole-2-carboxylic acid ethyl ester, (1-{ 6-[2-(2,4-dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -piperidin-3-yl)-acetic acid ethyl ester, N-(1-{ 6-[2-(2,4-Dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -piperidine-3-carbonyl)methanesulfonamide Ethanesulfonic acid (1-{ 6-[2-(2,4-dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} piperidine-3-carbonyl)-amide, 2-Methyl-propane-2-sulfonic acid (1-{ 6-[2-(2,4-dichlorophenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -piperidine-3-earbonyl)-amide, N-(1-{ 6-[2-(2,4-Dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -piperidine-3-carbonyl), trifluoro-methanesulfonamide, 1-{ 6-[2-(2,4-Dichloro-phenyl)-ethylamino]-2-methoxy-pyrlmidin-4-yl} -piperidine-3-carboxylic acid(IH-tetrazol-5-yl)-amide, 1-{ 6-[2-(2,4-Dichloro-phenyl)-ethylamino]-2-methoxy-pyrlmidin-4-yl} -piperidine-3-carboxylic acid amide, 1-{ 6-[2-(2,4-Dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -piperidine-3-carboxylic acid dimethylamide, N,N-Dimethylamide-2-sulfonic acid 1-{ 6-[2-(2,4-dichloro-phenyl)-ethylamino]-2-methoxypyrimidin-4-yl} -piperidine-3-carboxamide, 5-{ 2-Methoxy-6-[2-(4-tritluoromethoxy-phenyl)-ethylamino]-pyrimidin-4-yl} thiophene-2-carboxylic acid, or 5-{ 6-[2-(2,4-Dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -2,3-dihydrobenzofuran-2-carboxylic acid, or a pharmaceutically acceptable salt, hydrate, or solvate thereof. Also Use of the compound or a pharmaceutically acceptable salt, hydrate or solvate thereof according in the manufacture of a medicament for treating an allergic disease, systemic mastocytosis. a disorder accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, a disease accompanied by itch, a disease which is generated secondarily as a result of behaviour accompanied by itch, inflammation.,chronic obsttuctive pulmonary diseases, ischemic reperfusion injury cerebrovascular accident, chronic rheumatoid arthritism, pleurisy or ulcerative colitis.</abstract><oa>free_for_read</oa></addata></record>
fulltext	fulltext_linktorsrc
identifier
ispartof
issn
language	eng
recordid	cdi_epo_espacenet_NZ571793A
source	esp@cenet
subjects	CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title	2,6-substituted-4-monosubstituted amino-pyrimidine as prostaglandin D2 receptor antagonists
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T20%3A22%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=GARDNER,%20CHARLES%20J&rft.date=2011-08-26&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ENZ571793A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true